Drugs / IgPro20
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT06976476 | May 2025 → May 2029 expected | B cell deficiency, acquired immunodeficiency, plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04137224 | Sep 2019 → May 2022 | diffuse cutaneous systemic sclerosis | CSL Behring | Completed | No outcome recorded |
| Phase 39 trials · 2 met primary | ||||||
| Phase 3 | NCT07648264 | Jul 2026 → Feb 2029 expected | acquired immunodeficiency | CSL Behring | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06524739 | Aug 2024 → Jun 2025 | postural orthostatic tachycardia syndrome | CSL Behring | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT02027701 | Jul 2014 → Jul 2017 | chronic inflammatory demyelinating polyradiculoneuropathy, polyneuropathy, inflammatory demyelinating, chronic | CSL Behring | Completed | No outcome recorded |
| Phase 3 | NCT01545076 | Mar 2012 → Sep 2016 | polyneuropathy, inflammatory demyelinating, chronic, polyradiculoneuropathy | CSL Behring | Completed | Met primary |
| Phase 3 | NCT01199705 | Sep 2010 → Aug 2011 | immunodeficiency disease | CSL Behring | Completed | No outcome recorded |
| Phase 3 | NCT00751621 | Aug 2008 → Dec 2011 | immunodeficiency disease | CSL Behring | Completed | No outcome recorded |
| Phase 3 | NCT00719680 | Jun 2008 → Jun 2010 | immunodeficiency disease | CSL Behring | Completed | No outcome recorded |
| Phase 3 | NCT00542997 | Sep 2007 → Aug 2009 | Bruton-type agammaglobulinemia, autosomal agammaglobulinemia, common variable immunodeficiency | CSL Behring | Completed | No outcome recorded |
| Phase 3 | NCT00419341 | Nov 2006 → Oct 2008 | immunodeficiency disease | CSL Behring | Completed | Met primary |
| Phase 42 trials | ||||||
| Phase 4 | NCT07076446 | Jul 2025 → Jun 2026 | immunodeficiency disease | CSL Behring | Completed | No outcome recorded |
| Phase 4 | NCT03033745 | Feb 2017 → Dec 2018 | immunodeficiency disease | CSL Behring | Completed | No outcome recorded |
Press releases naming this drug 31 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IgPro20 | “Human Normal Immunoglobulin for Subcutaneous Administration (IgPro20) is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at...” NCT00419341 ↗12“evaluated the efficacy, tolerability, and safety of IgPro20 (Hizentra®; L-proline-stabilized 20 % human SCIG) in adult and pediatric Japanese patients with PID.” PMID 24504846 ↗ Feb 2014 “IgPro20 is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals.” NCT00542997 ↗ “IgPro20 is a solution for infusion for subcutaneous administration.” NCT07076446 ↗ |
| Known as | Hizentra | “IgPro20 (Subcutaneous Immunoglobulin, Hizentra®)” NCT04137224 ↗ |
| Modality | Protein / enzyme biologic | “Human Normal Immunoglobulin for Subcutaneous Administration (IgPro20) is a liquid formulation of normal human IgG” NCT00419341 ↗ |
| Route | Subcutaneous | “IgPro20 was administered subcutaneously once weekly” PMID 21553933 ↗ Jun 2011 |